Jacquet E, et al. - Researchers compared endocrine therapy and chemotherapy as first-line therapy in hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer patients using the Epidemiological Strategy and Medical Economics (ESME) program, UNICANCER, a large national observational database. They noted overall survival to be similar in this large retrospective cohort of patients with aromatase inhibitor-sensitive metastatic luminal breast cancer, irrespective of the first-line treatment (chemotherapy or endocrine therapy). Findings support the international guidelines recommending endocrine therapy as the first choice for first-line systemic treatment for metastatic breast cancer in the absence of visceral crisis.